Mercy110 wrote:. If folfiri is not working, then we don’t have anyway way out but keytruda, which is extremely expensive in Hong Kong. Seems that no more chemo way out...
You might not have any oncological society accepted or regulator approved
way out but keytruda, skipping over stivarga or Lonsurf, options with typically lots of side effects and low success rates.
There have been multiple, important technological avenues earlier that they didn't discuss, and probably have no informed inkling of an idea about them either:
1..Rolle's laser lung surgery
, somewhere overseas, mostly Germany.
2..Carbon ion beams
, Japan, are probably the highest therapeutic ratio radiation described, but are still more limited on tumor burden quantity than 1.
3..Lin's ADAPT therapy
, Xeloda + celecoxib. It really needs more adjuncts for more cancer inhibition effects and easiest tolerance but might have been a good choice even after several rounds of Folfox.
. Can include or modify #3 and can be modified for Kras mutation(s). Probably can include some Avastin but we haven't needed Avastin for cell kill. Even limited forms of metronomic, immunochemo with comfortable amounts of oral 5FU drug have succeeded in some percentage of late term cases after Folfox and Folfiri failed. The more advanced forms of immunochemo would target a cancer with particular mild drugs and high powered supplements. For Kras mutants, IV vitamin C infusions have been helpful.
We chose #4 for its broad coverage potential, low(est) side effects, easy home use, and low cost. The lung thingies disappeared early on, so we have no experience on higher tumor burden in the lungs.